1. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Issue 3 (March 2015) Authors: Rizvi, Naiyer A; Mazières, Julien; Planchard, David; Stinchcombe, Thomas E; Dy, Grace K; Antonia, Scott J; Horn, Leora; Lena, Hervé; Minenza, Elisa; Mennecier, Bertrand; Otterson, Gregory A; Campos, Luis T; Gandara, David R; Levy, Benjamin P; Nair, Suresh G; Zalcman, Gérard; Wolf, Jürgen; Souquet... Journal: Lancet oncology Issue: Volume 16:Issue 3(2015:Mar.) Page Start: 257 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Issue 3 (March 2015) Authors: Rizvi, Naiyer A; Mazières, Julien; Planchard, David; Stinchcombe, Thomas E; Dy, Grace K; Antonia, Scott J; Horn, Leora; Lena, Hervé; Minenza, Elisa; Mennecier, Bertrand; Otterson, Gregory A; Campos, Luis T; Gandara, David R; Levy, Benjamin P; Nair, Suresh G; Zalcman, Gérard; Wolf, Jürgen; Souquet... Journal: Lancet oncology Issue: Volume 16:Issue 3(2015:Mar.) Page Start: 257 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Peripheral blood immune cell dynamics reflect antitumor immune responses and predict clinical response to immunotherapy. Issue 6 (10th June 2022) Authors: Hwang, Michael; Canzoniero, Jenna Vanliere; Rosner, Samuel; Zhang, Guangfan; White, James R; Belcaid, Zineb; Cherry, Christopher; Balan, Archana; Pereira, Gavin; Curry, Alexandria; Niknafs, Noushin; Zhang, Jiajia; Smith, Kellie N; Sivapalan, Lavanya; Chaft, Jamie E; Reuss, Joshua E; Marrone, Kris... Journal: Journal for immunotherapy of cancer Issue: Volume 10:Issue 6(2022) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗